Preinfection human immunodeficiency virus (HIV)-specific cytotoxic T lymphocytes failed to prevent HIV type 1 infection from strains genetically unrelated to viruses in long-term exposed partners.
Understanding the mechanisms underlying potential altered susceptibility to human immunodeficiency virus type 1 (HIV-1) infection in highly exposed seronegative (ES) individuals and the later clinical consequences of breakthrough infection can provide insight into strategies to control HIV-1 with an effective vaccine. From our Seattle ES cohort, we identified one individual (LSC63) who seroconverted after over 2 years of repeated unprotected sexual contact with his HIV-1-infected partner (P63) and other sexual partners of unknown HIV-1 serostatus. The HIV-1 variants infecting LSC63 were genetically unrelated to those sequenced from P63. This may not be surprising, since viral load measurements in P63 were repeatedly below 50 copies/ml, making him an unlikely transmitter. However, broad HIV-1-specific cytotoxic T-lymphocyte (CTL) responses were detected in LSC63 before seroconversion. Compared to those detected after seroconversion, these responses were of lower magnitude and half of them targeted different regions of the viral proteome. Strong HLA-B27-restricted CTLs, which have been associated with disease control, were detected in LSC63 after but not before seroconversion. Furthermore, for the majority of the protein-coding regions of the HIV-1 variants in LSC63 (except gp41, nef, and the 3' half of pol), the genetic distances between the infecting viruses and the viruses to which he was exposed through P63 (termed the exposed virus) were comparable to the distances between random subtype B HIV-1 sequences and the exposed viruses. These results suggest that broad preinfection immune responses were not able to prevent the acquisition of HIV-1 infection in LSC63, even though the infecting viruses were not particularly distant from the viruses that may have elicited these responses.
Liu
Yi
Y
Department of Microbiology, University of Washington, Seattle, WA 98109, USA.
Woodward
Amanda
A
Zhu
Haiying
H
Andrus
Thomas
T
McNevin
John
J
Lee
Jean
J
Mullins
James I
JI
Corey
Lawrence
L
McElrath
M Juliana
MJ
Zhu
Tuofu
T
D003602:Cytotoxicity, Immunologic / Q000276:immunology; D014644:Genetic Variation; D015658:HIV Infections / Q000276:immunology* / Q000517:prevention & control* / Q000635:transmission / Q000821:virology; D020276:HIV Long-Term Survivors; D018023:HIV Seronegativity / Q000276:immunology*; D015497:HIV-1 / Q000145:classification / Q000235:genetics* / Q000276:immunology / Q000472:pathogenicity*; D015796:HLA-B27 Antigen / Q000378:metabolism; D006801:Humans; D008213:Lymphocyte Activation / Q000276:immunology; D008297:Male; D012725:Sexual Behavior; D012747:Sexual Partners; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology*; D047568:Unsafe Sex
D015796:HLA-B27 Antigen
J Clin Microbiol. 1988 Apr;26(4):662-7
2835389
Am J Epidemiol. 1997 Oct 15;146(8):655-61
9345119
Ann Intern Med. 1991 Oct 1;115(7):520-6
1652909
J Virol. 2005 Sep;79(18):11677-84
16140745
J Clin Invest. 1998 Nov 1;102(9):1758-65
9802890
AIDS Rev. 2003 Apr-Jun;5(2):87-103
12876898
JAMA. 2000 Feb 9;283(6):791-4
10683059
J Clin Invest. 2001 Feb;107(3):341-9
11160158
AIDS. 1999 Jan 14;13(1):23-9
10207541
Ann Intern Med. 1996 Aug 15;125(4):257-64
8678387
J Clin Invest. 2007 Nov;117(11):3563-75
17975674
J Exp Med. 2004 Apr 5;199(7):905-15
15067030
N Engl J Med. 1989 Jun 1;320(22):1458-62
2716797
Proc Natl Acad Sci U S A. 1999 Apr 13;96(8):4581-5
10200305
Science. 1997 Aug 15;277(5328):959-65
9252328
Immunogenetics. 2005 Apr;57(1-2):33-41
15744535
J Acquir Immune Defic Syndr. 2004 Apr 15;35(5):435-45
15021308
J Infect Dis. 1997 Oct;176(4):1093-6
9333175
J Virol. 2004 Feb;78(3):1324-32
14722287
Proc Natl Acad Sci U S A. 2001 Apr 24;98(9):5199-204
11320252
Nat Med. 1996 Nov;2(11):1240-3
8898752
J Virol. 1998 Jan;72(1):218-24
9420218
Nat Med. 1995 Jan;1(1):59-64
7584954
J Infect Dis. 1999 Mar;179(3):548-57
9952360
Immunol Cell Biol. 2000 Dec;78(6):586-95
11114968
J Clin Invest. 1994 Mar;93(3):1293-7
8132769
Lancet. 1993 Apr 3;341(8849):860-1
8096564
J Virol. 2003 Jun;77(11):6108-16
12743268
Immunol Lett. 1999 Mar;66(1-3):15-9
10203029
Science. 1996 Sep 27;273(5283):1856-62
8791590
J Immunol. 2003 Sep 1;171(5):2671-83
12928421
J Virol. 2004 Aug;78(15):7883-93
15254161
J Acquir Immune Defic Syndr. 1999 Jun 1;21(2):120-5
10360803
Immunol Lett. 2001 Nov 1;79(1-2):21-7
11595286
J Infect Dis. 2000 May;181(5):1581-9
10823757
Nat Med. 1997 Mar;3(3):338-40
9055864
Immunol Rev. 2000 Oct;177:99-111
11138790
J Clin Invest. 2001 May;107(10):1303-10
11375420
J Leukoc Biol. 2006 Nov;80(5):1118-26
17056765
AIDS. 2001 Feb 16;15(3):431-2
11273233
J Immunol. 2006 Nov 15;177(10):6588-92
17082569
J Infect Dis. 1994 Nov;170(5):1296-9
7963731
Cell. 1996 Aug 9;86(3):367-77
8756719
Immunol Lett. 2001 Nov 1;79(1-2):3-13
11595284
J Infect Dis. 2006 Mar 1;193(5):698-702
16453266
Nat Med. 1996 Apr;2(4):405-11
8597949
PLoS Med. 2006 Oct;3(10):e403
17076553
J Immunol. 2000 Feb 1;164(3):1602-11
10640781
J Acquir Immune Defic Syndr. 2001 Aug 15;27(5):472-81
11511825
AIDS. 2000 Dec 1;14(17):2671-8
11125885
J Infect Dis. 2004 Sep 15;190(6):1055-8
15319853
Annu Rev Genet. 2000;34:563-591
11092839
Immunol Lett. 1999 Mar;66(1-3):9-14
10203028
J Virol. 1999 Dec;73(12):10489-502
10559367
N Engl J Med. 2000 Mar 30;342(13):921-9
10738050
J Infect Dis. 1997 Feb;175(2):247-54
9203644
J Virol. 2007 Feb;81(4):2031-8
17108020
Blood. 1990 Nov 15;76(10):1924-6
2242420
Nature. 1996 Aug 22;382(6593):722-5
8751444
J Virol. 1999 Dec;73(12):10264-71
10559343
Science. 1998 Dec 4;282(5395):1907-11
9836644
Lancet. 1996 Nov 16;348(9038):1347-51
8918278
Nat Med. 1997 Nov;3(11):1250-7
9359700
Vaccine. 2003 Jun 1;21 Suppl 2:S68-76
12763686